Attovia Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Attovia Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Attovia Therapeutics, Inc. Common Stock (ATTO) has a Cash Flow-to-Debt Ratio of -1.08x as of June 2026, meaning its operating cash flow of $-16.79 Million could theoretically repay -1% of its total liabilities ($15.58 Million) in one year. See Attovia Therapeutics, Inc. Common Stock free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Attovia Therapeutics, Inc. Common Stock (2024–2025)
Cash flow-to-debt ratio of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025. Historical debt coverage capacity for Attovia Therapeutics, Inc. Common Stock across 2 annual periods. Also explore ATTO net assets growth trend to track the company's year-over-year net asset growth rate.
Attovia Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2024–2025)
Attovia Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2024 to 2025. Year-by-year debt coverage analysis for Attovia Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see Attovia Therapeutics, Inc. Common Stock cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.92x | $-59.20 Million | $15.10 Million | ▼ -63.2% |
| 2024 | -2.40x | $-35.03 Million | $14.59 Million | — |